Tabernero J, et al. - Among pts with PD-L1 combined positive score ≥1 (CPS ≥1), HER2-negative, advanced GC, researchers assessed the impacts of 1L P or P+C vs C in a randomized, active controlled study, KEYNOTE062. Using randomization 1:1:1, they assigned eligible pts to P 200 mg Q3W for up to 2 y, P+C (cisplatin 80 mg/m² + 5-FU 800 mg/m²/d on d1-d5 Q3W [or capecitabine 1000 mg/m² BID on d1-d14 Q3W per local guideline]) or placebo Q3W + C. OS in CPS ≥1 and CPS ≥10 for P+C vs C and P vs C and PFS (RECIST v1.1; central review) in CPS ≥1 for P+C vs C were considered as primary endpoints. Findings revealed the non-inferiority of P to C for OS in CPS ≥1 with clinically meaningful improvement for OS in CPS ≥10, when administered as 1L therapy for advanced GC. No superior OS and PFS in CPS ≥1 and OS in CPS ≥10 were demonstrated by P+C. P vs C displayed a more favorable safety profile.